Lilly might keep paying; Biotech vets seek jobs in clean tech;

> Clean tech looks like it could be the next big thing--for biotech workers. The two industries don't seem to have much in common, but BusinessWeek reports that a growing number of seasoned biotech veterans are leaving the biopharma industry to enter the growing clean tech field. Biotech report

> Yesterday's $62 million Zyprexa settlement might end up boosting another case related to off-label marketing of Zyprexa: a related civil and criminal investigation that might end with Eli Lilly paying more than $1 billion in fines and restitution. Report

> Novartis presented positive mid-stage data for NVA237, a lung disease treatment, at the annual European Respiratory Society (ERS) show in Berlin, Germany. The once-daily treatment sustained 24-hour bronchodilation in patients with moderate-to-severe COPD.  In addition, there were no clinically relevant cardiovascular problems. Novartis report

> The National Comprehensive Cancer Network will be looking at Abraxis BioScience Inc.'s breast cancer injectable drug, Abraxane, to look at its effectiveness as a treatment for various cancers, including breast, melanoma and non-small cell lung cancer. Report

> Accentia Biopharmaceuticals' subsidiary Biovest International announced positive results from its Phase 3 Fast-Tracked clinical trial of BiovaxID for the treatment of indolent follicular non-Hodgkin's lymphoma. The company intends to seek Accelerated Approval. Biovest report

> Analysts assess the damage after a Phase III clinical trial of the Avastin-Tarceva combo for the treatment of patients with advanced non-small cell lung cancer failed to hit its mark. Report

> France Biotech, the country's life sciences association, has released its report detailing the results of its annual survey. Expect more mergers between biotech and pharma in the coming months. And despite the global financial crisis, execs are optimistic that there will be more acquisitions, investments and IPOs. France Biotech report

> Shares of Oxford BioMedica jumped on the news that it's been conducting positive talks with the FDA on advancing clinical research on the renal cancer drug TroVax. The developer announced that the FDA supported all aspects of its amended plan for a Phase III. Oxford BioMedica report

>Alpharetta, GA-based AtheroGenics announced that it has consented to the Involuntary Chapter 7 Petition filed against the Company last month, and has filed to convert the matter to a case under Chapter 11 of the U.S. Bankruptcy Code. AntheroGenics report

> Anxious to push ahead with a slate of early-stage therapies, Eli Lilly struck a deal with India's Jubilant--a clinical research organization and manufacturer--to create a joint venture discovery firm. Eli Lilly report

> Circassia, a specialty biopharmaceutical company, announced today that it has acquired the U.S., Canadian and Japanese rights to dopexamine, a medication it hopes will improve patient recovery following certain high-risk surgeries. Report

And Finally... A new study published in the Canadian Medical Journal questions whether the C. difficile overgrowth consistently follows treatment with antibiotics, as commonly believed. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.